Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis
Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis
复制标题
DOI：
10.1507/endocrj.ej14-0088
复制
发表时间：
2014-07-01
影响因子：
2
通讯作者：
Akamizu, Takashi
中科院分区：
文献类型：
--
作者：
Ariyasu, Hiroyuki;Iwakura, Hiroshi;Akamizu, Takashi
大多数系统性硬化症（SSc）患者有胃肠道（GI）受累，但使用促动力剂的治疗通常不令人满意。Ghrelin刺激健康志愿者的胃运动。在这项研究中，我们调查了生长激素释放肽是否可以改善胃排空患者的胃肠道症状，由于SSc。本研究以随机、双盲、安慰剂对照交叉方式进行两次。10例胃肠道受累的SSc患者接受了Ghrelin（5.0 μ g/kg）或盐水的输注，并通过C-13-乙酸呼气试验评价胃排空率。在SSc患者中，胃饥饿素输注显著加速胃排空（胃饥饿素vs.生理盐水：43.3 +/- 11.4 min vs. 53.4 +/- 5.4 min，P=0.03）。未观察到严重不良反应。我们的研究结果表明，生长激素释放肽可能代表了一种新的治疗方法与SSc患者的胃肠道参与。
The majority of patients with systemic sclerosis (SSc) have gastrointestinal (GI) tract involvement, but therapies using prokinetic agents are usually unsatisfactory. Ghrelin stimulates gastric motility in healthy human volunteers. In this study, we investigated whether ghrelin could improve gastric emptying in patients with gastrointestinal symptoms due to SSc. The study was performed in a randomized, double-blind, placebo-controlled crossover fashion on two occasions. Ten SSc patients with GI tract involvement received an infusion of either ghrelin (5.0 mu g/kg) or saline, and gastric emptying rate was evaluated by C-13-acetic acid breath test. Gastric emptying was significantly accelerated by ghrelin infusion in patients with SSc (ghrelin vs. saline: 43.3 +/- 11.4 min vs. 53.4 +/- 5.4 min, P=0.03). No serious adverse effects were observed. Our results suggest that ghrelin might represent a new therapeutic approach for GI tract involvement in patients with SSc.